Background: Amiodarone is a frequently used antiarrhythmic drug in patients with end-stage heart failure. Given its long half-life, pre-transplant use of amiodarone has been controversially discussed, with divergent results regarding morbidity and mortality after heart transplantation (HTX).
Aim: The aim of this study was to investigate the effects of long-term use of amiodarone before HTX on early post-transplant atrial fibrillation (AF) and mortality after HTX.
Methods: Five hundred and thirty patients (age ≥18 years) receiving HTX between June 1989 and December 2012 were included in this retrospective single-center study. Patients with long-term use of amiodarone before HTX (≥1 year) were compared to those without long-term use (none or <1 year of amiodarone). Primary outcomes were early post-transplant AF and mortality after HTX. The Kaplan-Meier estimator using log-rank tests was applied for freedom from early post-transplant AF and survival.
Results: Of the 530 patients, 74 (14.0%) received long-term amiodarone therapy, with a mean duration of 32.3±26.3 months. Mean daily dose was 223.0±75.0 mg. Indications included AF, Wolff-Parkinson-White syndrome, ventricular tachycardia, and ventricular fibrillation. Patients with long-term use of amiodarone before HTX had significantly lower rates of early post-transplant AF (P=0.0105). Further, Kaplan-Meier analysis of freedom from early post-transplant AF showed significantly lower rates of AF in this group (P=0.0123). There was no statistically significant difference between patients with and without long-term use of amiodarone prior to HTX in 1-year (P=0.8596), 2-year (P=0.8620), 5-year (P=0.2737), or overall follow-up mortality after HTX (P=0.1049). Moreover, Kaplan-Meier survival analysis showed no statistically significant difference in overall survival (P=0.1786).
Conclusion: Long-term use of amiodarone in patients before HTX significantly reduces early post-transplant AF and is not associated with increased mortality after HTX.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762580 | PMC |
| http://dx.doi.org/10.2147/DDDT.S96126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Profile and Management of Wolf-Parkinson White Syndrome and Asymptomatic Pre-Excitation Carriers in Africa: A Multicenter Pan African Registry From 17 Countries.
J Cardiovasc Electrophysiol
January 2025
Douala Gyneco-obstetric and Pediatric Hospital/University of Douala, Douala, Cameroon.
Article Synopsis
- The study explores the management and diagnosis of Wolf-Parkinson White Syndrome (WPW) and asymptomatic pre-excitation in Africa, highlighting a lack of data in the region.
- Conducted in 20 centers across 17 African countries, the research involved 541 participants and focused on symptomatology, treatment approaches, and the impact of local health dynamics on care.
- Results indicated that a vast majority were diagnosed with WPW, with significant regional differences in treatment options and effectiveness, showing that Northern and Southern Africa have more advanced practices compared to other areas.
Changes in Hepatic Density Due to Oral Amiodarone-induced Liver injury Shown by Computed Tomography.
Intern Med
November 2024
Internal Medicine II, Faculty of Medicine, Shimane University, Japan.
Amiodarone is an antiarrhythmic drug that is widely used for atrial fibrillation and other refractory arrhythmias. Although beneficial, its long-term administration is associated with adverse effects on various organs. One patient presented with amiodarone-induced liver injury, which led to liver failure.
View Article and Find Full Text PDFComputer-Aided Identification and Design of Ligands for Multi-Targeting Inhibition of a Molecular Acute Myeloid Leukemia Network.
Cancers (Basel)
October 2024
Izmir Biomedicine and Genome Center, 35340 Balçova, İzmir, Türkiye.
Background/objectives: Acute myeloid leukemia (AML) is characterized by therapeutic failure and long-term risk for disease relapses. As several therapeutic targets participate in networks, they can rewire to eventually evade single-target drugs. Hence, multi-targeting approaches are considered on the expectation that interference with many different components could synergistically hinder activation of alternative pathways and demolish the network one-off, leading to complete disease remission.
View Article and Find Full Text PDFBackground The Swiss Society of General Internal Medicine (SGAIM) has chosen the topic "Recognising drug interactions and preventing side effects" as a quality indicator in the primary care setting. Methodology Retrospectively, in a group practice of 6 general practitioners (GPs), all patients aged 65 and over who were prescribed ≥ 5 long-term medications were identified in the year 2022. These medications were systematically checked for interaction reports using the Compendium® software.
View Article and Find Full Text PDFDrug-drug-interactions in patients with atrial fibrillation admitted to the emergency department.
Front Pharmacol
October 2024
Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.
Introduction: Polypharmacy is a growing concern in healthcare systems. While available data on potential drug-drug interactions (pDDI) from emergency department (ED) patients is derived from heterogenous populations, this study specifically focused on patients with atrial fibrillation (AF). We hypothesized that patients with AF have similar comorbidities, receive similar drugs, and have similar pDDIs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!